The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer

Hasbek, Zekiye; Doğan, Ömer Tamer; Sarı, İsmail; Yücel, Birsen; Şeker, Mehmet Metin; Turgut, Bülent; Berk, Serdar; Siliğ, Yavuz
October 2016
Molecular Imaging & Radionuclide Therapy;Oct2016, Vol. 25 Issue 3, p107
Academic Journal
Objective: Mutations in the p53 gene are the most commonly observed genetic abnormalities in malignancies. The purpose of this study was to assess the diagnostic value of serum anti-p53 antibody (Ab) along with the correlation between serum anti-p53 Ab level and quantitative positron emission tomography (PET) parameters such as maximum standardized uptake value (SUVmax), SUVave, metabolic tumor volume, total lesion glycolysis (TLG) and tumor size. Methods: Serum anti-p53 Ab level was studied in three groups. Patients who underwent 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) imaging for staging of previously diagnosed lung cancer constituted the first group, while patients who underwent 18F-FDG PET/CT imaging for evaluation of suspicious pulmonary nodules detected on thorax CT and did not show pathologic FDG accumulation (NAPN=pulmonary nodule with non avid-FDG) were enrolled in the second group. The third group consisted of healthy volunteers. Results: Twenty-eight patients with lung cancer (median age: 62.5, range: 39-77years), 28 patients with NAPN (median age: 65, range: 33-79 years), and 24 healthy volunteers (median age: 62, range: 44-74 years) were enrolled in the study. The serum anti-p53 Ab level was low in healthy volunteers while it was higher in both lung cancer patients and NAPN patients (p<0.05). When serum anti-p53 Ab level and PET parameters were evaluated, there was no significant correlation between serum anti-p53 Ab level and SUVmax, SUVave, TLG, tumor volume and tumor size of patients with lung cancer (p>0.05). Besides, there was no significant difference between serum anti-p53 Ab level and lesion size of NAPN patients (p>0.05). Conclusion: It was determined that serum anti-p53 Ab levels are not significantly correlated with PET parameters, and that serum anti-p53 Ab levels increase in any benign or malignant lung parenchyma pathology as compared to healthy volunteers. These results indicate that this Ab cannot be used as a predictor of malignancy in a lung lesion.


Related Articles

  • Colorectal carcinoma with special reference to growth pattern classifications: clinicopathologic characteristics and genetic changes. Kurahashi, Toshinori; Kaneko, Kazuhiro; Makino, Reiko; Mitamura, Keiji // Journal of Gastroenterology;2002, Vol. 37 Issue 5, p354 

    Background: Many colorectal carcinomas are known to develop from preexisting polypoid adenomas; however, they can also develop from so-called “flat adenomas”. To elucidate the growth patterns of flat- or depressed-derived colorectal carcinomas, we investigated the clinicopathologic...

  • PI3K/Akt-mediated regulation of p53 in cancer. Abraham, Aswin G.; O'Neill, Eric // Biochemical Society Transactions;Aug2014, Vol. 42 Issue 4, p798 

    Mutations activating the PI3K (phosphoinositide 3-kinase)/Akt signalling pathway and inactivating the TP53 tumour-suppressor gene are common mechanisms that cancer cells require to proliferate and escape preprogrammed cell death. In a well-described mechanism, Akt mediates negative control of...

  • p53 in the game of transposons. Wylie, Annika; Jones, Amanda E.; Abrams, John M. // BioEssays;Nov2016, Vol. 38 Issue 11, p1111 

    Throughout the animal kingdom, p53 genes function to restrain mobile elements and recent observations indicate that transposons become derepressed in human cancers. Together, these emerging lines of evidence suggest that cancers driven by p53 mutations could represent 'transpospoathies,' i.e....

  • Investigations on a clinically and functionally unusual and novel germline p53 mutation. Rutherford, J.; Chu, C.E.; Duddy, P.M.; Charlton, R.S.; Chumas, P.; Taylor, G.R.; Lu, X.; Barnes, D.M.; Camplejohn, R.S. // British Journal of Cancer;5/20/2002, Vol. 86 Issue 10, p1592 

    This report describes an individual with a rare choroid plexus papilloma in adulthood (age 29) after earlier having an osteosarcoma (age 22). The results from this study, and others, suggest that it may be advisable to consider the possibility of a germline p53 mutation in adults presenting with...

  • The p53 Mutation Which Abrogates Trans-Activation While Maintaining Its Growth-Suppression Activity. Sang-Jin Oh; Min-Young Im // Molecules & Cells (Springer Science & Business Media B.V.);2000, Vol. 10 Issue 4, p386 

    Presents a study which focused on the p53 mutation which abrogates trans-activation while maintaining its growth-suppression activity. Materials and methods; Results; Discussion.

  • Characterization of a new intrabody directed against the N-terminal region of human p53. Cohen, Pascale A; Mani, Jean-Claude; Lane, David P // Oncogene;11/12/98, Vol. 17 Issue 19, p2445 

    Genes encoding the rearranged immunoglobulin heavy and light chain variable regions of DO-1, a monoclonal antibody directed against human p53, have been used to construct a single-chain antibody. DO-1 recognizes an N-terminal epitope in the region involved in the transactivation function of p53...

  • Monoclonal antibodies raised against Xenopus p53 interact with human p73. Le Bras, Morgane; Delattre, Valerie; Bensaad, Karim; Blandino, Giovanni; Soussi, Theirry // Oncogene;2/14/2002, Vol. 21 Issue 8, p1304 

    Presents a study that examined a panel of monoclonal antibodies raised against human and Xenopus p53 which cross-react strongly with human p73. Paralogues of the p53 tumor suppressor gene; Analysis of mutations in the p53 gene; Role of monoclonal antibodies in studying the structure-function...

  • p53 mutations implicate sunlight in post-transplant skin cancer irrespective of human papillomarivus status. McGregor, Jane M; Berkhout, Ron JM; Rozycka, Magdalena; ter Schegget, Jan; Bavinck, Jan N Bouwes; Brooks, Louise; Crook, Tim // Oncogene;10/2/97, Vol. 15 Issue 14, p1737 

    Mutations in p53 were detected in 11/23 (48%) of non melanoma skin cancers in renal allograft recipients and in 5/8 (63%) of sporadic tumours from immune competent patients. 9/12 (75%) of mutations in transplant patients and all 5 mutations in non transplant tumours were consistent with damage...

  • Induction of Ovarian Leiomyosarcomas in Mice by Conditional Inactivation of Brca1 and p53. Quinn, Bridget A.; Brake, Tiffany; Xiang Hua; Baxter-Jones, Kimberly; Litwin, Samuel; Ellenson, Lora Hedrick; Connolly, Denise C. // PLoS ONE;2009, Vol. 4 Issue 12, p1 

    Background: Approximately one out of every ten cases of epithelial ovarian cancer (EOC) is inherited. The majority of inherited cases of EOC result from mutations in the breast cancer associated gene 1 (BRCA1). In addition to mutation of BRCA1, mutation of the p53 gene is often found in patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics